11,494 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. purchased a new stake in Applied Therapeutics, Inc. (NASDAQ:APLT) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 11,494 shares of the company’s stock, valued at approximately $54,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Principal Financial Group Inc. purchased a new position in shares of Applied Therapeutics in the 2nd quarter worth about $54,000. Jump Financial LLC bought a new position in Applied Therapeutics during the 4th quarter worth approximately $81,000. SG Americas Securities LLC bought a new position in shares of Applied Therapeutics in the 2nd quarter worth about $87,000. Denali Advisors LLC acquired a new stake in shares of Applied Therapeutics during the 1st quarter worth approximately $228,000. Finally, EntryPoint Capital LLC bought a new position in Applied Therapeutics in the 1st quarter worth about $272,000. Hedge funds and other institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Price Performance

Applied Therapeutics stock opened at $8.11 on Wednesday. The business has a 50 day simple moving average of $5.89 and a 200 day simple moving average of $5.34. Applied Therapeutics, Inc. has a one year low of $1.79 and a one year high of $9.39. The company has a market capitalization of $926.13 million, a PE ratio of -4.40 and a beta of 2.03.

Applied Therapeutics (NASDAQ:APLT) last announced its earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $10.00 million. Equities analysts anticipate that Applied Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on APLT shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Applied Therapeutics in a research note on Wednesday, July 17th. William Blair upgraded shares of Applied Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Leerink Partners boosted their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Finally, Citigroup lifted their target price on shares of Applied Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Applied Therapeutics has a consensus rating of “Buy” and a consensus price target of $12.50.

Insider Buying and Selling at Applied Therapeutics

In other news, CEO Shoshana Shendelman sold 300,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $5.98, for a total value of $1,794,000.00. Following the transaction, the chief executive officer now directly owns 5,167,853 shares in the company, valued at approximately $30,903,760.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.60% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.